Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma

The purpose of this prospective, multicenter, Phase 2 study is to evaluate the efficacy and safety of Mosunetuzumab in combination with the EZH2 inhibitor Zeprumetostat (SHR2554) in patients with follicular lymphoma (FL). The study plans to enroll approximately 80 patients, who will be assigned to three distinct cohorts: previously untreated high-risk FL (Cohort 1), previously untreated low-tumor-burden FL (Cohort 2), and relapsed or refractory FL (Cohort 3). The study consists of a safety run-in phase, which will be initially conducted in Cohort 1 to assess the tolerability of the combination

Trial Details

NCT ID

NCT07555470

Phase

PHASE2

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

Mosunetuzumab
Zeprumetostat

Locations (sample)

Tianjin, Tianjin Municipality, China|39.14222,117.17667
Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

Age ≥ 18 years
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
Adequate hematologic and organ function
Female subjects of childbearing potential must have a negative serum pregnancy test and agree to use highly effective contraception; male subjects …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →